• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Artelo Biosciences Inc. (Amendment)

    2/23/22 4:36:39 PM ET
    $ARTL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ARTL alert in real time by email
    SC 13G/A 1 c103099_sc13ga.htm
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
     
    SCHEDULE 13G
     
     
    Under the Securities Exchange Act of 1934
     
    (Amendment No. 1)*
     

    Artelo Biosciences, Inc.

    (Name of Issuer)
     

    Common Stock, $0.001 par value

    (Title of Class of Securities)
     

    04301G201

    (CUSIP Number)
     

    December 31, 2021

    (Date of event which requires filing of this statement)
     
    Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed:
     
    o Rule 13d-1(b)
    x Rule 13d-1(c)
    o Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     
    CUSIP No. 04301G201    
         
    1

    NAMES OF REPORTING PERSONS

    Iroquois Capital Management L.L.C.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) o

    (b) o

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

     

    6

    SHARED VOTING POWER

    100,000 shares of Common Stock issuable upon exercise of Warrants (See Item 4)

    7

    SOLE DISPOSITIVE POWER

     

    8

    SHARED DISPOSITIVE POWER

    100,000 shares of Common Stock issuable upon exercise of Warrants (See Item 4)

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    100,000 shares of Common Stock issuable upon exercise of Warrants (See Item 4)

     

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES o
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0.24% (See Item 4)*

     

    12

    TYPE OF REPORTING PERSON

    OO

     

                                                                         
     
    CUSIP No. 04301G201    
         
    1

    NAMES OF REPORTING PERSONS

    Richard Abbe

     

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) o

    (b) o

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

     

    6

    SHARED VOTING POWER

    100,000 shares of Common Stock issuable upon exercise of Warrants (See Item 4)

    7

    SOLE DISPOSITIVE POWER

     

    8

    SHARED DISPOSITIVE POWER

    100,000 shares of Common Stock issuable upon exercise of Warrants (See Item 4)

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    100,000 shares of Common Stock issuable upon exercise of Warrants (See Item 4)

     

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES o
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0.24% (See Item 4)*

     

    12

    TYPE OF REPORTING PERSON

    IN; HC

                                                                           
     
    CUSIP No. 04301G201    
         
    1

    NAMES OF REPORTING PERSONS

    Kimberly Page

     

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) o

    (b) o

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

     

    6

    SHARED VOTING POWER

    100,000 shares of Common Stock issuable upon exercise of Warrants (See Item 4)

     

    7

    SOLE DISPOSITIVE POWER

     

    8

    SHARED DISPOSITIVE POWER

    100,000 shares of Common Stock issuable upon exercise of Warrants (See Item 4)

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    100,000 shares of Common Stock issuable upon exercise of Warrants (See Item 4)

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES o
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0.24% (See Item 4)*

     

    12

    TYPE OF REPORTING PERSON

    IN

                                                                           
     
    CUSIP No. 04301G201    
         

    This Amendment No. 1 (this “Amendment”) amends the statement on Schedule 13G filed on October 19, 2020 (the “Original Schedule 13G”) with respect to the Common Stock, $0.001 par value (the “Common Stock”) of Artelo Biosciences, Inc. (the “Company”). Capitalized terms used herein and not otherwise defined in this Amendment have the meanings set forth in the Original Schedule 13G. This Amendment amends and restates each of Item 4 and Item 5 in its entirety as set forth below.

     

    Item 4. OWNERSHIP.
       
     

    The information as of the date of the event which requires filing of this statement required by Items 4(a) – (c) is set forth in Rows 5 – 11 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person. The percentage set forth in Row 11 of the cover page for each Reporting Person is based on 42,301,013 shares issued and outstanding as of January 10, 2022 as reported by the Issuer in its Quarterly Report on Form 10-Q for the quarter ended November 30, 2021, filed by the Issuer with the SEC on January 12, 2022, and assumes the exercise of the Company’s reported warrants (the “Reported Warrants”).

     

    As of the date of the event which requires filing of this statement, Iroquois Master Fund Ltd. (“Iroquois Master Fund”) held Reported Warrants to purchase 100,000 shares of Common Stock. Mr. Abbe shares authority and responsibility for the investments made on behalf of Iroquois Master Fund with Ms. Kimberly Page, each of whom is a director of the Iroquois Master Fund. As such, Mr. Abbe and Ms. Page may each be deemed to be the beneficial owner of all shares of Common Stock held by Iroquois Master Fund. Iroquois Capital is the investment advisor for Iroquois Master Fund and Mr. Abbe is the President of Iroquois Capital. As such, Mr. Abbe may be deemed to be the beneficial owner of all shares of Common Stock held by Iroquois Master Fund. The foregoing should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of shares of Common Stock owned by another Reporting Person. Each of the Reporting Persons hereby disclaims any beneficial ownership of any such shares of Common Stock except to the extent of their pecuniary interest therein.

     
    CUSIP No. 04301G201    

     

    Item 5. Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following:  x

     

    Item 10. CERTIFICATION.
       
      Each of the Reporting Persons hereby makes the following certification:
       
      By signing below each Reporting Person certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
     
    CUSIP No. 04301G201    

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: February 22, 2022

     

      IROQUOIS CAPITAL MANAGEMENT L.L.C.  
         
      By:   /s/ Richard Abbe
     
     
      Richard Abbe, President  
         
        /s/ Richard Abbe
     
     
      Richard Abbe  
         
        /s/ Kimberly Page
     
     
      Kimberly Page  
     
    Get the next $ARTL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ARTL

    DatePrice TargetRatingAnalyst
    7/8/2025$20.00Hold → Buy
    D. Boral Capital
    11/1/2021$4.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $ARTL
    SEC Filings

    View All

    SEC Form DEF 14A filed by Artelo Biosciences Inc.

    DEF 14A - ARTELO BIOSCIENCES, INC. (0001621221) (Filer)

    12/11/25 4:05:26 PM ET
    $ARTL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Artelo Biosciences Inc.

    EFFECT - ARTELO BIOSCIENCES, INC. (0001621221) (Filer)

    12/3/25 12:15:09 AM ET
    $ARTL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Artelo Biosciences Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    8-K - ARTELO BIOSCIENCES, INC. (0001621221) (Filer)

    11/25/25 4:05:41 PM ET
    $ARTL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARTL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Artelo Biosciences Announces Publication of New Peer-Reviewed Study Demonstrating Intraperitoneal Administration of a Novel Fatty Acid Binding Protein 5 (FABP5) Inhibitor Significantly Reduces Stress-Induced Anxiety and Depression Behaviors in Preclinical Models

    SOLANA BEACH, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ:ARTL) ("Artelo" or the "Company"), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological, or neurological conditions, today announced the publication of new peer-reviewed research from the laboratory of Dr. Steven Laviolette, Professor in the Schulich School of Medicine at the University of Western Ontario, Canada, partially funded by the Company, demonstrating that intraperitoneal administration of Artelo's proprietary FABP5 inhibitor SBFI103 produces robust anxiolytic and antidepressant-like eff

    12/3/25 8:30:00 AM ET
    $ARTL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Artelo Biosciences Provides Business Update and Reports Third Quarter 2025 Financial Results

    SOLANA BEACH, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today provided a business update and announced its financial and operational results for the three months ended September 30, 2025. "We continue to deliver on our clinical and strategic objectives, advancing three differentiated programs with strong potential to address large, underserved markets," said Gregory D. Gorgas, President and Chief Executive Officer of Artelo Biosciences. "We were very pleased with

    11/12/25 8:00:00 AM ET
    $ARTL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Artelo Biosciences Announces Publication of Peer-Reviewed Article on Role of Fatty Acid Binding Proteins in Cancer

    SOLANA BEACH, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ:ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological, or neurological conditions, announces the publication of a peer-reviewed article, "The Emerging Role of Fatty Acid Binding Protein 3 (FABP3) in Cancers", in Drug Discovery Today. The publication's lead author is Dr. George Warren, Principal Scientist at Artelo. This publication marks the third in a trilogy of reviews exploring the protumoral roles of FABP isoforms 3, 5, and 7 in cancer biology. This publication underscores growing evid

    11/4/25 8:30:00 AM ET
    $ARTL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARTL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Spring Mark Edward

    3 - ARTELO BIOSCIENCES, INC. (0001621221) (Issuer)

    11/17/25 5:30:44 PM ET
    $ARTL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Matsui Connie

    4 - ARTELO BIOSCIENCES, INC. (0001621221) (Issuer)

    10/30/25 9:30:05 PM ET
    $ARTL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Favorito Tamara A

    4 - ARTELO BIOSCIENCES, INC. (0001621221) (Issuer)

    10/30/25 9:28:31 PM ET
    $ARTL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARTL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Artelo Biosciences upgraded by D. Boral Capital with a new price target

    D. Boral Capital upgraded Artelo Biosciences from Hold to Buy and set a new price target of $20.00

    7/8/25 8:21:40 AM ET
    $ARTL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HC Wainwright & Co. initiated coverage on Artelo Biosciences with a new price target

    HC Wainwright & Co. initiated coverage of Artelo Biosciences with a rating of Buy and set a new price target of $4.00

    11/1/21 6:29:39 AM ET
    $ARTL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LADENBURG THALM/SH SH initiated coverage on Artelo Biosciences

    LADENBURG THALM/SH SH initiated coverage of Artelo Biosciences with a rating of Buy

    2/12/21 7:33:23 AM ET
    $ARTL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARTL
    Leadership Updates

    Live Leadership Updates

    View All

    Artelo Biosciences Names Veteran Life Sciences Executive Mark Spring, CPA, as Chief Financial Officer

    SOLANA BEACH, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ:ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological, or neurological conditions, today announced the appointment of Mark Spring, CPA, as Chief Financial Officer, effective November 1, 2025. Mr. Spring had been serving as a financial consultant to the Company since December 2024. The appointment strengthens Artelo's financial leadership as it advances its clinical pipeline and corporate growth initiatives. Mark Spring brings 30 years of experience in life sciences to his role, including f

    10/27/25 8:00:00 AM ET
    $ARTL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kintara Therapeutics Appoints Tamara A. Seymour to Board of Directors

    SAN DIEGO, May 4, 2021 /PRNewswire/ -- Kintara Therapeutics, Inc. (NASDAQ:KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced the appointment of Tamara A. Seymour to the Company's Board of Directors replacing John Liatos, who will continue in his role as Kintara's Senior Vice President of Business Development. "We are delighted to welcome Tamara to the Board of Directors as she brings exceptional healthcare sector experience as an accomplished financial and operational executive," comm

    5/4/21 8:00:00 AM ET
    $KTRA
    $ARTL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Artelo Biosciences Appoints Finance and Healthcare Industry Executive Tamara A. Seymour to Board of Directors

    LA JOLLA, Calif., March 09, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system, today announced the appointment of Tamara A. Seymour, CPA, to the Company’s board of directors. “We are pleased to welcome Tamara to Artelo’s board of directors,” said Connie Matsui, Board Chair. “Tamara brings with her an impressive track record in corporate finance and capital markets, as well as extensive experience guiding biopharmaceutical and diagnostic companies from clinical stage to commercialization. We believe her advice a

    3/9/21 8:30:00 AM ET
    $ARTL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARTL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Artelo Biosciences Inc. (Amendment)

    SC 13G/A - ARTELO BIOSCIENCES, INC. (0001621221) (Subject)

    2/23/22 4:36:39 PM ET
    $ARTL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Artelo Biosciences Inc. (Amendment)

    SC 13G/A - ARTELO BIOSCIENCES, INC. (0001621221) (Subject)

    2/9/22 11:08:31 AM ET
    $ARTL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Artelo Biosciences Inc. (Amendment)

    SC 13G/A - ARTELO BIOSCIENCES, INC. (0001621221) (Subject)

    2/4/22 3:19:12 PM ET
    $ARTL
    Biotechnology: Pharmaceutical Preparations
    Health Care